Although many biopharmaceutical companies leverage in-house capabilities to produce their therapies, contract manufacturing partners represent a significant part of the biologics industry. Recent capacity investments, facility expansions, and mergers and acquisitions (M&A) activity even suggest that third-party biologics production is gaining traction. In this eBook, BioProcess Insider’s founding editor, Dan Stanton, takes the pulse of today’s outsourcing sector. First, he speaks with Dawn Ecker (director of bioTRAK database services at BDO) to establish what kinds of companies are amassing mammalian and/or microbial cell-culture capacity. Entries from the database reveal not only that contract manufacturing organizations (CMOs) are making gains in total global capacity, but also that many established pharmaceutical companies continue to use internal capacity to manufacture other companies’ products. Stanton follows up on those findings by exploring the origins of a hybrid developer–manufacturer business model that complicates traditional conceptions of biopharmaceutical outsourcing. Stanton interviews Anton Gerdenitsch (global head of contract manufacturing at Novartis) to learn about the rationale behind such a business model and to understand why large pharmaceuticals have only recently begun publicly promoting contract services. Stanton also speaks with industry analysts from GlobalData PharmSource to understand how contract manufacturers might fare as SARS-CoV-2 becomes endemic and as current public health crises subside. Read the complete eBook now to learn more about the continuing evolution of the biopharmaceutical outsourcing business model and competitive landscape.
Fill out the form below to read the complete eBook now.
You May Also Like
